Prognosis
Very poor in general; variable according to the translocation, the phenotype, the age, and whether the leukaemia is de novo or secondary.
Cytogenetics
Cytogenetics, morphological -+11: 1% of ANLL and MDS as well; M1, M2, and M4 ANLL; therapy related ANLL; MDS evolving towards ANLL; partial tandem duplication (in situ) of MLL; visible dup(11q) also occur.
-inv(11)(p15q23): rare; ANLL and MDS. -t(X;11)(q13;q23): rare; ANLL; the gene involved in Xq13 is AFX1, a transcription regulator. -t(1;11)(p32;q23): rare; ALL and ANLL; the gene involved in 1p32 is AF1P. -t(1;11)(q21;q23): rare; mostly M4 ANLL; the gene involved in 1q21 is AF1q. -t(2;11)(p21;q23): rare; ANLL and MDS; may be found associated with del(5q). -t(3;11)(p21;q23): very rare; involve AF3p21. -t(4;11)(q21;q23): represent 1/3 of cases; found mainly (95%) in B-ALL (CD19+ in 75%, CD10+ in 15%); treatment related ALL in 5%; unbalanced sex ratio < 4 yrs (1M/2F); children represent half cases (infants (<1 yr) accounting for 1/3 of all cases); children aged 2-9 yrs appear to have a much better prognosis; the gene involved in 4q21 is AF4, a transcription activator. -t(6;11)(q27;q23): 5% of cases; mostly; children and young adults; male predominance; the gene involved in 6q27 is AF6; role in signal transduction. -t(9;11)((p23;q23): represent 1/4 of cases; found in ANLL mainly in M5a (70%), or M4 (10%); in ALL in 10%; de novo and therapy related AL; children represent half cases (infants (<1 yr) accounting for 15% of all cases); the gene involved in 9p22 is AF9, a transcription activator. -t(10;11)(p12;q23): 5% of cases; M4 or M5 ANLL; ALL at times; from infants and children to (rare) adult cases; the gene involved in 10p12 is AF10, a transcription activator. -t(11;16)(q23;p13): rare; treatment related ANLL/MDS; most cases are children cases; the gene involved in 16p13 is CBP, a transcriptional adaptor/coactivator. -t(11;17)(q23;q21): rare; ANLL; the gene involved in 17q21 is AF17; not to be confused with the t(11;17)(q23;q21) in M3 ANLL variant, with involvement of PLZF in 11q23 and RARa in 17q21. -t(11;17)(q23;q25): rare; ANLL and MDS. -t(11;19)(q23;p13.1): 5% of cases; M4 or M5 ANLL most often; de novo and therapy related AL; adults mainly; the gene involved in 19p13.1 is ELL, a transcription activator. -t(11;19)(q23;p13.3): 5% of cases; ALL, biphenotypic AL and ANLL (M4/M5 mainly); therapy related AL; T-cell ALL at times, these T-cell cases are the only cases of t(11;19) with an excellent prognosis, a rather rare feature in this page!!; mostly found in infants (half cases), and other children (altogether: 70%), or young adults (cases 40 yrs are 4%; 23 unpublished cases and review of 90 cases); the gene involved in 19p13.3 is ENL, a transcription activator. Various other poorly known 11q23 rearrangements have been described: -t(5;11)(q31;q23), -t(6;11)(q21;q23): ANLL; the gene involved in 6q21 is AF6q21, a transcription regulator, -t(10;11)(q22;q23), -t(11;11)(q13;q23), -t(11;12)(q23;q13), -t(11;15)(q23;q15), -t(11;17)(q23;p13), -t(11;18)(q23;q23), -t(11;21)(q23;q11), -t(11;22)(q23;q13): ANLL; the gene involved in 22q13 is P300. Various other breakpoints with 11q23 are: Xq22, 1q32, 2q37, 8q11, 9p11, 9q33, 12p13, 14q11, 14q32, 17q11, 18q12, 20q13, … Additional anomalies +X and i(7q) in the t(4;11); +8, +19, +21 in the t(6;11); +8 and +19 in the t(9;11); inv(11) in the t(10;11); +X, +6 and +8 in the 19p13.3; +8 in the 19p13.1.
Genes involved and Proteins

MLL
Location: in 11q23 DNA / RNA 21 exons, spanning over 100 kb; 13-15 kb mRNA; coding sequence: 11.9 kb. Protein 431 kDa; contains two DNA binding motifs (a AT hook, and Zinc fingers), a DNA methyl transferase motif, a bromodomain; transcriptional regulatory factor; nuclear localisation; wide expression; homology with trithorax (drosophila).
Variable gene, from a variable chromosome partner (see above)
DNA / RNA These genes appear to have, in most cases, no apparent homology to each other; for DNA and protein description of each, refer to their gene entry.
Results of the chromosomal anomaly
Hybrid gene
Description 5' MLL -3' partner; highly variable breakpoints on the partner.
Fusion protein
Description N-term AT hook and DNA methyltransferase from MLL fused to (little or most of) the partner C-term part; the reciprocal (partner-MLL) may or may not be expressed.
